Fig. 5

(A–B) Maximum projections of neuromasts from sost:NTR-GFP; sost:nlsEos fish at 3 dpf (A) and 5 dpf (B). Sost:NTR-GFP cells are shown in green and sost:nlsEos cells are shown in magenta. Arrowheads indicate cells expressing sost:nlsEos but not sost:NTR-GFP. Scale bar = 10 μm. (C) Support cells per neuromast expressing either NTR-GFP and nlsEos (green) or nlsEos only (magenta) at 3 dpf and 5 dpf. NTR-GFP/nlsEos: 9.04 ± 2.39 (3 dpf) vs. 8.47 ± 2.27 (5 dpf), n = 49 neuromasts each (10 fish each); nlsEos only: 6.10 ± 2.27 (3 dpf) vs. 10.86 ± 2.72 (5 dpf), n = 49 neuromasts each (10 fish each); mean ± SD; Kruskal-Wallis test, Dunn’s post-test, p>0.9999 (NTR-GFP/nlsEos 3 dpf vs. 5 dpf), p<0.0001 (nlsEos only 3 dpf vs. 5 dpf). (D–F) Maximum projections of neuromasts from sost:NTR-GFP; sost:nlsEos fish following mock treatment (D; Mock), Mtz at 5 dpf (E; Mtz5), and Mtz at 3 dpf and 5 dpf (F; Mtz3/5). Sost:NTR-GFP cells are shown in green and sost:nlsEos cells are shown in magenta. Scale bar = 10 μm. (G) Support cells per neuromast solely expressing sost:nlsEos following Mtz treatment. Mock: 11.18 ± 2.04, n = 50 neuromasts (10 fish); Mtz5: 9.72 ± 2.03, n = 50 neuromasts (10 fish); Mtz3/5: 6.76 ± 2.12, n = 50 neuromasts (10 fish); mean ±SD; Kruskal-Wallis test, Dunn’s post-test, p=0.0288 (Mock vs. Mtz5), p<0.0001 (Mock vs. Mtz3/5, Mtz5 vs. Mtz3/5).